- About Us
- Nano-Social Network
- Nano Consulting
- My Account
ULURU INC. reported financial results today for the quarter and six months ended June 30, 2007.
For the quarter ended June 30, 2007, the net loss attributable to common stockholders was $1,209,000, or $0.02 per share, compared to a net loss of $1,612,000, or $0.13 per share, for corresponding period in 2006. For the six months ended June 30, 2007, the net loss was $2,056,000, or $0.03 per share, compared to a net loss of $4,530,000, or $0.38 per share, for the six months ended June 30, 2006. The net loss was impacted by non-cash expenses related to stock options accounted for in accordance with SFAS 123(R) "Share Based Payment" of $119,000 and $221,000, for the quarter and six months ended June 30, 2007, respectively (compared with no expense for the corresponding periods in 2006), and by the amortization of our intangible assets of $269,000 and $534,000 for the quarter and six months ended June 30, 2007, respectively.
Revenues for the second quarter of 2007 were $119,000, compared with $312,000 for the same period last year. The decrease of $193,000 is primarily due to lower licensing fees as a result of a non-recurring milestone of $155,000 for Zindaclin(R) in 2006 and the lack of Aphthasol(R) product sales to our domestic distributor in 2007 due to timing of product orders. These items were partially offset by an increase in royalties associated with the international sales of Zindaclin(R) along with an increase in sponsored research.
Total costs and expenses increased by $216,000 in the second quarter 2007 to $1,533,000, compared with the corresponding period in 2006 where total costs and expenses were $1,317,000. General and administrative expenses were responsible for this increase, as these expenses increased from $463,000 in the second quarter 2006 to $694,000 in 2007, a $231,000 increase. Increased costs include legal expenses for patent prosecution ($82,000), and expenses related to being a public company, including director fees ($71,000), annual report and annual meeting expenses ($31,000). Research and development costs increased from $478,000 in the second quarter 2006 to $554,000 in 2007. The $76,000 increase is primarily due to fees payable to the Food and Drug Administration of $58,000 and increased compensation expense of $30,000. Cost of product sales declined by $97,000 in 2007 reflecting no shipments to our distributor in the 2007 period.
Interest and miscellaneous income increased significantly in second quarter 2007 to $206,000, compared with $3,000 for the same period last year. The increase of $203,000 is attributable to our increased liquidity due to the recapitalization of the Company in December 2006.
There was no interest expense for the three months ended June 30, 2007 as compared to the expense of $610,000 for the same period last year. The decrease in interest expense relates to the payoff in December 2006 of our outstanding secured convertible debentures.
Cash and cash equivalents totaled $16,261,000 at June 30, 2007, a decrease of $657,000 as compared to our cash and cash equivalents at December 31, 2006 of $16,918,000. The decrease in net cash for the six months ended June 30, 2007 was due to several factors: the expenditure of $531,000 for the purchase of manufacturing equipment for commercial scale-up of our OraDisc(TM) products, the $350,000 payment in April 2007 of our original asset purchase obligation, and the net cash used for operations of approximately $51,000. These net cash decreases were partially offset by proceeds of $275,000 from the exercise of warrants to purchase our common stock.
Commenting on the quarterly results, Kerry P. Gray, President and CEO stated, "Our loss from operations was significantly lower than our operating plan despite our revenues being marginally lower than our expectations due primarily to sponsored research payments. Expense control and the development of study plans that offer the best potential returns on our research investment have contributed to this positive variance. We expect our operating expenses to increase over the balance of this year as we expand our organization and clinical study program to take advantage of our product opportunities."
Since the last quarterly report there has been significant progress both in the area of business development and in product development:
-- Three corporate development agreements have been signed.
* A consumer products agreement
* A veterinary products agreement
* An advanced wound care agreement
-- Clinical studies of our wound dressing product have commenced
-- Our clinical study program has been expanded to include studies in
chronic wounds with the VA Hospitals.
-- Two additional product formulations have been developed:
* In conjunction with a partner we have developed a nanoparticle spray
* We have expanded our wound care product line to include a preformed
sized wound dressing with the same properties as our powder
-- We have initiated a porcine study to determine the optimal material
characteristics for the clinical development of a range of dermal
fillers that we anticipate will provide longer periods between
Gray continued, "The Company made significant business development and technical advances in the second quarter which exceeded our expectations. In addition to the announced agreements great progress has been made in numerous high value areas to expand our partnering network. The technical achievements provide us with additional opportunities for product candidates and the ability to make further improvements in our wound dressing. The preformed wound dressing product offers a convenient alternative to our powder product for various wound types and provides for additional drug delivery opportunities which we feel has exciting potential to expand our market opportunity."
About ULURU Inc
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com .
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating) relating to future product and financial performance of ULURU Inc. (the "Company" expected increases in our operating expenses and business development and technical advances. When used in this press release, the words "may," "targets," "goal," "could," "should," "would," "believe," "feel," "expects," "confident," "anticipate," "estimate," "intend," "plan," "potential" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the progress of our technology with corporate partners favorably impacting 2007 performance, pre-clinical results for our products and advantages of our products. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. The Company cautions that various factors, including the factors described hereunder and those discussed in the Company's other filings with the Securities and Exchange Commission, as well as general economic conditions, industry trends, collect accounts receivable, hire and retain qualified personnel, Food and Drug Administration regulations, adverse litigation, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements of the Company made by or on behalf of the Company. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. New factors emerge from time to time, and it is not possible for management to predict all of such factors. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by us with the Securities and Exchange Commission.
ULURU Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2007 2006 2007 2006 REVENUES License fees $16,831 $155,037 $154,880 $155,037 Royalty income 81,456 69,943 136,918 252,115 Product sales 0 75,578 0 75,578 Other 20,501 11,664 210,501 96,656 Total Revenues 118,788 312,222 502,299 579,386 COSTS AND EXPENSES Cost of goods sold 0 96,520 0 96,520 Research and development 553,755 477,725 1,119,163 954,121 General and administrative 693,588 462,878 1,288,826 745,907 Amortization 268,630 262,550 534,173 519,724 Depreciation 17,173 17,173 33,877 31,898 Total Costs and Expenses 1,533,146 1,316,846 2,976,039 2,348,170 OPERATING (LOSS) (1,414,358) (1,004,624) (2,473,740) (1,768,784) Other Income (Expense) Interest and miscellaneous income 205,825 2,830 419,630 11,210 Interest expense 0 (610,461) (1,574) (984,464) Commitment fee - Standby Equity Agreement 0 0 0 (1,787,940) NET (LOSS) $(1,208,533) $(1,612,255)$(2,055,684) $(4,529,978) Basic and diluted net (loss) per common share $(0.02) $(0.13) $(0.03) $(0.38) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 61,916,935 12,844,311 61,326,745 11,937,440 ULURU Inc. SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA March 31, 2007 December 31, 2006 (Unaudited) (Audited) Cash and cash equivalents $16,260,910 $16,918,007 Current assets 16,799,292 17,856,476 Property and equipment, net 1,182,199 691,132 Other assets 11,591,298 12,119,618 Total assets 29,572,789 30,667,226 Current liabilities 1,323,997 1,382,003 Long term liabilities - deferred revenue 523,005 0 Total liabilities 1,847,002 1,382,003 Total stockholders' equity 27,725,787 29,285,223
For more information, please click here
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016